The influence of age and gender on remifentanil EC(50) for preventing rocuronium induced withdrawal movements

So Jin Park, Hye Jin Park, Ju Youn Choi, Hyo Seok Kang, Hong Seok Choi, So Jin Park, Hye Jin Park, Ju Youn Choi, Hyo Seok Kang, Hong Seok Choi

Abstract

Background: Rocuronium-induced withdrawal movements can be harmful to patients during the induction period. Remifentanil has been reported to reduce these movements effectively. In this study, we determined the EC(50) of remifentanil for the prevention of rocuronium induced withdrawal movements in male, female, old and child group.

Methods: We included patients scheduled for general anesthesia and assigned them into 4 groups depending on their age and gender: male group (20-60 yr), female group (20-60 yr), old group (>65 yr) and child group (6-12 yr). Remifentanil was administered by target controlled infusion. Propofol 2 mg/kg was then administered after equilibration between the effect and plasma concentration of remifentanil was reached. After loss of consciousness, rocuronium 0.6 mg/kg was administered. Patient's response to the rocuronium was graded using a 4 point scale in a blinded manner. The EC(50) of remifentanil for preventing rocuronium induced withdrawal movements was determined using Dixon's up-and -down method.

Results: The EC(50) of remifentanil for preventing rocuronium induced withdrawal movements was 1.8 +/- 0.5 ng/ml [95% confidence interval 1.3-2.2] in the male group, 2.3 +/- 1.0 ng/ml [1.3-3.2] in the female group, 0.5 +/- 0.4 ng/ml [0.2-0.8] in the old group and 2.8 +/- 0.8 ng/ml [2.1-3.5] in the child group.

Conclusions: The EC(50) of remifentanil for preventing rocuronium induced withdrawal movements was lowest in the elderly and higher in children than male adult patients. No difference in the EC(50) of remifentanil was seen between male and female adult patients.

Keywords: Remifentanil; Rocuronium; Withdrawal movements.

Figures

Fig. 1
Fig. 1
Consecutive target remifentanil concentrations for determining the EC50. The arrow represents the mean remifentanil concentration when crossing from significant movements (grade 2,3) to no movements (grade 0,1). The average of these concentrations is the EC50. EC50 is 1.8 ± 0.5 ng/ml in male adult, 2.3 ± 1.0 ng/ml in female adult, 0.5 ± 0.4 ng/ml in old and 2.8 ± 0.8 ng/ml in child group.
Fig. 2
Fig. 2
Dose response curves plotted from probit analysis of individual remifentanil concentration and respective reaction to rocuronium injection. M: male, F: female, O: old, C: child.

References

    1. Steegers MA, Robertson EN. Pain on injection of rocuronium bromide. Anesth Analg. 1996;83:203.
    1. Reddy MS, Chen FG, Ng HP. Effect of ondansetron pretreatment on pain after rocuronium and propofol injection: a randomised, double-blind controlled comparison with lidocaine. Anaesthesia. 2001;56:902–905.
    1. Chiarella AB, Jolly DT, Huston CM, Clanachan AS. Comparison of four strategies to reduce the pain associated with intravenous administration of rocuronium. Br J Anaesth. 2003;90:377–379.
    1. Moorthy SS, Dierdorf SF. Pain on injection of rocuronium bromide. Anesth Analg. 1995;80:1067.
    1. Borgeat A, Kwiatkowski D. Spontaneous movements associated with rocuronium: is pain on injection the cause? Br J Anaesth. 1997;79:382–383.
    1. Egan TD. Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. Clin Pharmacokinet. 1995;29:80–94.
    1. Oh AY, Seo KS, Goo EK, Park YO, Kim SJ, Kim JH. Prevention of withdrawal movements associated with injection of rocuronium in children: comparison of remifentanil, alfentanil and fentanyl. Acta Anaesthesiol Scand. 2007;51:1190–1193.
    1. Mencke T, Beerhalter U, Fuchs-Buder T. Spontaneous movements, local reactions and pain on injection of rocuronium. A comparison between female and male patients. Acta Anaesthesiol Scand. 2001;45:1002–1005.
    1. Mencke T, Schreiber JU, Knoll H, Stracke C, Kleinschmidt S, Rensing H, et al. Women report more pain on injection of a precurarization dose of rocuronium: a randomized, prospective, placebo-controlled trial. Acta Anaesthesiol Scand. 2004;48:1245–1248.
    1. Kim KS, Kim YS, Jeon WJ, Yeom JH. Prevention of withdrawal associated with the injection of rocuronium in adults and children. J Clin Anesth. 2006;18:334–338.
    1. Minto CF, Schnider TW, Egan TD, Youngs E, Lemmens HJ, Gambus PL, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology. 1997;86:10–23.
    1. Choi BI, Choi SH, Shin YS, Lee SJ, Yoon KB, Shin SK, et al. Remifentanil prevents withdrawal movements caused by intravenous injection of rocuronium. Yonsei Med J. 2008;49:211–216.
    1. Dixon WJ. Staircase bioassay: the up-and-down method. Neurosci Biobehav Rev. 1991;15:47–50.
    1. Blunk JA, Seifert F, Schmelz M, Reeh PW, Koppert W. Injection pain of rocuronium and vecuronium is evoked by direct activation of nociceptive nerve endings. Eur J Anaesthesiol. 2003;20:245–253.
    1. Ahmad N, Choy CY, Aris EA, Balan S. Preventing the withdrawal response associated with rocuronium injection: a comparison of fentanyl with lidocaine. Anesth Analg. 2005;100:987–990.
    1. Memiş D, Turan A, Karamanlioğlu B, Süt N, Pamukçu Z. The prevention of pain from injection of rocuronium by ondansetron, lidocaine, tramadol, and fentanyl. Anesth Analg. 2002;94:1517–1520.
    1. Minto CF, Schnider TW, Shafer SL. Pharmacokinetics and pharmacodynamics of remifentanil. II. Model application. Anesthesiology. 1997;86:24–33.
    1. Giles BE, Walker JS. Gender differences in pain. Curr Opin Anaesthesiol. 1999;12:591–595.
    1. Dahan A, Kest B, Waxman AR, Sarton E. Sex-specific responses to opiates: animal and human studies. Anesth Analg. 2008;107:83–95.

Source: PubMed

3
Sottoscrivi